Leber's Hereditary Optic Neuropathy Clinical Trial
Official title:
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
Hypotheses: The primary hypothesis being tested is that there will be no toxicity resulting in loss of vision to no light perception in injected eyes.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01421381 -
RHODOS Follow-up Single-visit Study
|
N/A | |
Completed |
NCT00747487 -
Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy
|
Phase 2 | |
Completed |
NCT04909398 -
Pupil Dynamics and Color Vision for the Detection of Eye Diseases
|
N/A | |
Completed |
NCT02693119 -
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
|
Phase 2 | |
Withdrawn |
NCT01495715 -
Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
|
Phase 3 | |
No longer available |
NCT04381091 -
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study
|
||
No longer available |
NCT02300753 -
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
|
N/A |